Allan Hillgrove, Boehringer Ingelheim on what pharma should learn from the Tamiflu controversy

Allan Hillgrove, Corporate Board, Pharma Marketing & Sales at Boehringer Ingelheim on what the industry needs to learn from the controversy over Tamiflu.

Please login to view video - or subscribe here

To view the full video you need eyeforpharma Premium. Get On Demand now

comments powered by Disqus